Upon development of neurological symptoms, mice were deeply anesthetized before perfusion with cold DPBS followed by 1% PFA. Brains were rapidly dissected in cold DPBS and then fixed in 100% MeOH at 4 °C overnight. Samples were rehydrated at 4 °C in DPBS for 4 h before embedding in 3% low-melt agarose gel (IBI scientific, #B70051). 150 um thick free-floating sections were cut using a Leica vibratome. Floating sections were incubated in blocking solution (PBS + 0.5% Triton x-100 + 10% normal donkey serum) at RT for 30 min before incubating with primary antibodies at 4 °C overnight. The next day sections were washed in DPBS, transferred to blocking solution containing the appropriate secondary antibodies (1:500) and incubated at room temperature for 2 h. Finally, sections were incubated in Hoechst (1:1000 in PBS) for 10 min before final DPBS washing and mounting onto slides (Fisher, Superfrost), and coverslipped (Prolong Gold Antifade, ThermoFisher). Primary antibodies used in this study include: eGFP (Aves, #GFP1020), CD31 (BD Biosciences, #550,274), Glut1 (Millipore, #07–1401), Collagen IV (BioRad, #161,115), Desmin (Cell Signaling, #5332), human Vimentin (eBioscience, #11–9897-82), Claudin-5 (Thermofisher, #352,588), Plvap (BD Biosciences, #550,274), Ter119 (Invitrogen #14–5921-82) and Hoechst (ThermoFisher). Corresponding secondary antibodies used were all purchased from Jackson ImmunoResearch. Images were acquired on a confocal microscope (Nikon A1), and image analysis was performed in NIH Image J. Statistical analyses of these data were performed in GraphPad prism as described in the manuscript. P-values of ≤ 0.05 were considered statistically significant.
For histology, mouse brain tissue was fixed in 10% formalin overnight and transferred to 70% ethanol before paraffin embedding. 5 μm thick sections were prepared on a microtome (Lecia), and processed for hematoxylin–eosin (H&E) staining. For immunohistochemistry of primary patient samples 5 µm thick paraffin sections were prepared and stained using standardized techniques. Primary antibodies used include anti-CD31 (Dako, #M0823), anti-Cldn5 (Invitrogen, #34–1600) and anti-Glut1 (Millipore, #07–1401). Stains were developed with secondary HRP and DAB immunoreactivity secondary kits (Dako) and counterstained with Hematoxylin before mounting.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.